| ID | 1215 |
| Name of the vaccine | dmLT |
| Microbe | Bacteria |
| Disease name | E.coli Infections |
| Name of bacteria | Escherichia coli |
| Type of vaccine | Recombinant |
| Nucleic acid content | Circular duplex DNA |
| Age | 18 to 45 years |
| Description of the vaccine | Recombinant double mutant heat-labile toxin LT(R192G/L211A) (dmLT) Oral enterotoxigenic Escherichia coli (ETEC) vaccine. |
| Name of the manufacturer | National Institute of Allergy and Infectious Diseases (NIAID) |
| Name of the manufacturing country | United States |
| Year of manufacture | 2016 |
| Clinical Phase status | Clinical - Phase 1 |
| Bacterial strain | Gram-negative, rod-shaped bacteria. |
| Efficacy | NA |
| Vaccine formulation | NA |
| Dosage | Three doses over a range of dosages. |
| Mechanism of action | NA |
| Route of administration | Sublingual |
| Indications | NA |
| Export | NA |
| Approval | NA |
| Adjuvant | NA |
| Repurposing | NA |
| Side effects of vaccine | Diarrhoea, pain or bruising, gastrointestinal symptoms like nausea, abdominal pain, decreased appetite. |
| Post vaccination | NA |
| Dose type | Combination doses |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NCT02052934 |
| Reference | NA |
| Other name | NA |
| Additional Links | NA
|